肿瘤细胞治疗研究
ALL SOURCES
Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance.
免疫检查点阻断改变了宫颈癌的治疗格局，但临床获益仍存在异质性，且难以用单一生物标志物预测。
Immune Predictors of Radiotherapy Outcomes in Cervical Cancer.
免疫微环境影响患者对放疗（RT）的敏感性，但治疗耐药的决定因素仍不清楚。
GBP6 maintains mitochondrial bioenergetics to promote immune evasion from NK cells in cervical cancer.
代谢重编程和免疫逃逸是癌症进展的核心标志；然而，线粒体代谢如何塑造免疫逃逸仍不清楚。
The impact of gut microbiota on cervical cancer and precancerous lesions: neglected status, mechanisms, challenges, and a call to action.
宫颈癌（CC）仍是与持续高危型人乳头瘤病毒（HPV）感染密切相关的全球重大健康威胁。
Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation
纵向免疫变化，而非单纯的基线差异，可区分应答者与非应答者。
α-GalCer-LNP ehanced mRNA delivery and activates natural killer T cells for superior tumor immunotherapy.
在TC-1宫颈癌模型中，G-LNP使100%的治疗小鼠实现完全肿瘤消退（标准LNP为42.85%），并对肿瘤再接种提供长期保护（持续>100天）。
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
尽管疗效有限，monalizumab联合durvalumab耐受性良好，且在外周血和TME中观察到了令人鼓舞的免疫激活。
A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillo
经改造以表达肿瘤反应性T细胞受体（TCR）的免疫细胞，作为单一疗法针对实体瘤的疗效有限。
Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis.
我们的研究表明，肿瘤可能通过产生无细胞毒性的GSDMB亚型来阻断和逃避杀伤细胞触发的细胞焦亡。
Adoptive Cell Therapy for Nonhematologic Solid Tumors.
免疫疗法在部分肿瘤中展现的长期益处未能推广到大多数非血液系统实体瘤。
MEMBER ACCOUNT
登录成功会直接打开下一页。
